Harnessing innate immune pathways for therapeutic advancement in cancer

Ankang Hu,Li Sun,Hao Lin,Yuheng Liao,Hui Yang,Ying Mao

DOI: https://doi.org/10.1038/s41392-024-01765-9

IF: 39.3

2024-03-25

Signal Transduction and Targeted Therapy

Abstract:The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and specific cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reflects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Refining our understanding of the tumor's innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to clinical application.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the application and complexity of the innate immune pathway in cancer treatment. Specifically:

1. **Limitations of clinical applications**: Although drugs targeting the innate immune pathway have shown significant efficacy in pre - clinical studies, in clinical trials, the success rate of these drugs is still limited. The paper explores the reasons behind this phenomenon, including the heterogeneity of the innate immune pathway in different tumor development stages, pathway states, and specific cell types.

2. **Dual effects of activating the innate immune pathway**: Interestingly, recent studies have shown that activating the innate immune pathway sometimes promotes tumor progression. This contradictory phenomenon requires further study to understand the underlying mechanisms.

3. **Diversity of the innate immune pathway**: The paper points out that the innate immune pathway in the tumor microenvironment (TME) exhibits multi - dimensional diversity, which is rooted in cellular heterogeneity and manifested as multiple signal networks. This diversity leads to the fact that the innate immune pathway may promote tumor growth in some cases and inhibit tumor growth in others.

4. **Optimization of targeting strategies**: In order to better utilize the anti - tumor potential of the innate immune pathway, the paper proposes that a more refined understanding of the innate immune pathway network in tumors is required and appropriate targeting strategies should be adopted. This includes combining multi - target therapies to overcome abnormal tumor signal pathways.

In summary, this paper aims to provide new ideas and strategies for future clinical applications by in - depth exploration of the role and complexity of the innate immune pathway in cancer treatment.